The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.
Concentration:
0.5 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C. Do not freeze.
Each lot of this antibody is quality control tested by ELISA assay. For ELISA detection applications, a concentration range of 0.5-2.0 μg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-12 p40 recombinant protein ranging from 4000 to 30 pg/ml are recommended for each ELISA plate. To obtain a linear standard curve, serial dilutions of IL-12 p70 recombinant protein ranging from 1000 to 8 pg/ml are recommended for each ELISA plate. For use as an ELISPOT detection antibody, a concentration range of 1-4 μg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
ELISA or ELISPOT Detection1,2: The biotinylated C8.6 antibody is useful as a detection antibody for an IL-12 p40 specific sandwich ELISA or ELISPOT assay, when used in conjunction with the C8.3 antibody (Cat. No. 501702/501704) as the capture antibody. The biotinylated C8.6 antibody is useful as a detection antibody for an IL-12 p70 specific sandwich ELISA or ELISPOT assay, when used in conjunction with the purified 7B12 antibody (Cat. No. 511002/511004) as the capture antibody. Biotin-F(ab') (Cat. No. 508805) is recommended for ELISA analysis of human serum and plasma samples, to prevent non-specific binding of interfering substances such as rheumatoid factor and heterophilic antibodies. Each lot of this antibody is quality control tested by ELISA assay. Neutralization1,3,4: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm sterile-filtered) is recommended for neutralization of human IL-12 bioactivity (Cat. No. 508804).
Additional reported applications (for the relevant format) include: immunoprecipitation4, Western blotting1. Note: For testing human IL-12/IL-23 p40 (monomer, dimer) in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430701 to 430706) are specially developed and recommended. For testing human IL-12 p70 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 431701 to 431706) are specially developed and recommended.
Application References:
1. D'Andrea, A., et al., 1992. J. Exp. Med. 176: 1387. 2. D'Andrea, A., et al., 1993. J. Exp. Med. 178: 1041. 3. Goodier, M., et al., 2000. J. Immunol. 165: 139. 4. Aragane, Y., et al., 1994. J. Immunol. 153: 5366.
Description:
The C8.6 antibody reacts with human IL-12 p40 subunit of the IL-12 p70 heterodimer and IL-23 p40 subunit of the IL-23 p19/p40, as well as p40 monomer and homodimer. The C8.6 antibody has been reported to strongly inhibit different biological activities of IL-12, (e.g., IFN-gamma induction, mitogenic effects on PHA blasts, and enhancement of NK cell-mediated cytotoxicity). The C8.6 antibody can neutralize the bioactivity of natural or recombinant IL-12.
Cytokine; monomer, heterodimer (p40:p35 or p40:p19) or homodimer (p40:p40)
Regulation:
Downregulated by IL-10; homodimeric p40 antagonistic to functional p70 heterodimer; p40 monomer has no function; p40 subunit in common with IL-23
Cellular Sources:
Dendritic cells, monocytes/macrophages, B cells, T cells
Cellular Targets:
T cells, NK cells, PBL
Receptors:
IL-12Rβ1 binds p40; dimeric with IL-12Rβ2 binds p35
Bioactivity/Activities:
IL-12 p70 (p40:p35) induces IFN-γ, TNF-a production in T and NK cells; costimulation of PBL proliferation; proliferation/differentiation of TH1 T lymphocytes. IL-23 (p40:p19) induces proliferation and production of IFN-γ by human me
Antigen References:
1. Fitzgerald, K., et al., Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. Quesniaux, V. 1992. Research Immunol. 143:385. 3. Trinchieri, G., et al., 1992 Prog. Growth Factor Res. 4:355. 4. Trinchieri, G., et al., 1993 Immunol. Today. 14:335. 5. Oppmann, B., et al., 2000 Immunity. 13:715. 6. Aggarwal, S., et al., 2003 J. Biol. Chem.. 278:1910. 7. Parham, C., et al., 2002 J. Immunol.. 168:5699. 8. Belladonna, M.L., et al., 2002 J. Immunol.. 168:5448. 9. Lankford, C.S., et al., 2003 J. Leukoc. Biol.. 73:49.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
